Urogen Pharma (NASDAQ:URGN) Given a $41.00 Price Target at Stifel Nicolaus

Stifel Nicolaus set a $41.00 price objective on Urogen Pharma (NASDAQ:URGN) in a report published on Sunday morning, TipRanks reports. The firm currently has a buy rating on the stock.

A number of other analysts have also weighed in on the company. HC Wainwright set a $75.00 price objective on Urogen Pharma and gave the company a buy rating in a research note on Monday. ValuEngine raised Urogen Pharma from a hold rating to a buy rating in a research note on Thursday, August 1st. Zacks Investment Research lowered Urogen Pharma from a hold rating to a sell rating in a research note on Saturday. Finally, Cowen reissued a buy rating on shares of Urogen Pharma in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. Urogen Pharma has an average rating of Buy and a consensus price target of $56.25.

NASDAQ URGN traded up $0.03 on Friday, reaching $21.81. 136,041 shares of the company’s stock traded hands, compared to its average volume of 208,093. Urogen Pharma has a 12 month low of $20.72 and a 12 month high of $55.49. The stock has a 50-day simple moving average of $27.92 and a 200 day simple moving average of $33.32. The stock has a market cap of $463.49 million, a PE ratio of -4.54 and a beta of 1.14.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Friday, August 9th. The company reported ($1.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.12. The company had revenue of $0.02 million for the quarter. On average, equities analysts predict that Urogen Pharma will post -4.95 EPS for the current fiscal year.

In related news, CFO Peter P. Pfreundschuh sold 1,416 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $33.07, for a total value of $46,827.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.50% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC lifted its position in Urogen Pharma by 50.2% during the second quarter. ARK Investment Management LLC now owns 13,529 shares of the company’s stock valued at $486,000 after buying an additional 4,522 shares during the period. Highline Capital Management L.P. lifted its position in Urogen Pharma by 2.8% during the second quarter. Highline Capital Management L.P. now owns 1,014,078 shares of the company’s stock valued at $36,446,000 after buying an additional 27,200 shares during the period. LLBH Private Wealth Management LLC lifted its position in Urogen Pharma by 76.9% during the second quarter. LLBH Private Wealth Management LLC now owns 17,692 shares of the company’s stock valued at $636,000 after buying an additional 7,692 shares during the period. JPMorgan Chase & Co. purchased a new position in Urogen Pharma during the second quarter valued at $170,000. Finally, BlackRock Inc. lifted its position in Urogen Pharma by 216.8% during the second quarter. BlackRock Inc. now owns 1,338,553 shares of the company’s stock valued at $48,107,000 after buying an additional 915,970 shares during the period. 70.31% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

See Also: Asset Allocation, Balancing Your Investments

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.